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Abstract
CD8
+ T cell responses to vaccinia virus are directed almost exclusively against early gene products. The attenuated strain
modified vaccinia virus Ankara (MVA) is under evaluation in clinical trials of new vaccines designed to elicit cellular immune
responses against pathogens including Plasmodium spp., M. tuberculosis and HIV-1. All of these recombinant MVAs (rMVA)
utilize the well-established method of linking the gene of interest to a cloned poxviral promoter prior to insertion into the
viral genome at a suitable locus by homologous recombination in infected cells. Using BAC recombineering, we show that
potent early promoters that drive expression of non-functional or non-essential MVA open reading frames (ORFs) can be
harnessed for immunogenic expression of recombinant antigen. Precise replacement of the MVA orthologs of C11R, F11L,
A44L and B8R with a model antigen positioned to use the same translation initiation codon allowed early transgene
expression similar to or slightly greater than that achieved by the commonly-used p7.5 or short synthetic promoters. The
frequency of antigen-specific CD8
+ T cells induced in mice by single shot or adenovirus-prime, rMVA-boost vaccination were
similarly equal or marginally enhanced using endogenous promoters at their authentic genomic loci compared to the
traditional constructs. The enhancement in immunogenicity observed using the C11R or F11L promoters compared with
p7.5 was similar to that obtained with the mH5 promoter compared with p7.5. Furthermore, the growth rates of the viruses
were unimpaired and the insertions were genetically stable. Insertion of a transgenic ORF in place of a viral ORF by BAC
recombineering can thus provide not only a potent promoter, but also, concomitantly, a suitable insertion site, potentially
facilitating development of MVA vaccines expressing multiple recombinant antigens.
Citation: Orubu T, Alharbi NK, Lambe T, Gilbert SC, Cottingham MG (2012) Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by
Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA. PLoS ONE 7(6): e40167. doi:10.1371/journal.pone.0040167
Editor: Bruno Verhasselt, Ghent University, Belgium
Received January 25, 2012; Accepted June 2, 2012; Published June 27, 2012
Copyright:  2012 Orubu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded in part by a Grand Challenges in Global Health grant to Prof. Adrian V. S. Hill, Jenner Institute, University of Oxford administered
by the Foundation for the National Institutes of Health. MGC and TL are supported by the Oxford Martin School. SCG is a Jenner Investigator. The authors are
grateful to the Jenner Institute’s Vector Core Facility, funded by the Wellcome Trust, for technical assistance. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: MGC is a named inventor on a patent application relating to the method described (United Kingdom Patent Application No. 1006405.3
‘‘Poxvirus expression system’’). SCG is a named inventor on a patent relating to prime-boost vaccination (WO9856919 ‘‘Methods and reagents for vaccination
which generate a CD8 T cell immune response’’). This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials..
* E-mail: matt.cottingham@ndm.ox.ac.uk
Introduction
The year 1983 saw the first descriptions of viral vectored
vaccines, employing recombinant vaccinia virus to express foreign
genes and elicit immune responses against various target
pathogens [1–3]. Two different methods for expression of a cloned
cDNA in vaccinia virus were employed in these inaugural studies,
though both relied on insertion by homologous recombination in
virus-infected cells. Whereas B. Moss’ group fused the cDNA of
interest to a promoter prior to incorporation into vaccinia virus
[2,3], E. Paoletti and colleagues relied on endogenous transcrip-
tional activity near the viral insertion locus [1,4].
The disadvantage of using an endogenous promoter in the
1980s was that transgene expression by recombinants could be
detected even when not adjacent to a transcriptional regulatory
sequence [1,5]. Using the technology and knowledge of the day, it
was hard to avoid inserting extra sequence upstream of the
transgene, so this phenomenon was attributed either to accidental
presence of a sequence with weak promoter activity in the inserted
sequence, or to formation of a fusion protein [5]. The linking of
a cloned viral promoter and ORF of interest prior to insertion
therefore became the standard method for generation of
recombinant vaccinia virus [6]. Essentially the same technique,
with variations, has been applied to other poxviruses [7]. Despite
its sterling service in the eradication of smallpox, vaccinia virus
lacks the improved human safety profile of attenuated derivatives
such as NYVAC and MVA [8] or of avian poxviruses [9]. Yet as
recombinants, these too have typically employed the p7.5
promoter, as in 1983, or one of a small number of other
promoters with early/late activity, for example, H5 (previously
called H6) [10], modified H5 (mH5) [11] and the short synthetic
promoter (SSP) [12] to drive transgene expression. The cassette is
generally still inserted into the traditional thymidine kinase (TK)
locus, or into one of a similarly limited number of alternative
loci: in MVA, into one of the sites of the large genomic deletions
[13], or more recently into an intergenic region [14–15].
The application of BAC recombineering technology to cloned
poxviral genomes [16–18], coupled with recent transcriptomic
studies [19–21], has allowed us to revisit the endogenous promoter
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increased precision of modern methodology allows direct re-
placement of a viral ORF with a coding sequence of interest, such
that the initiation codon lies in exactly the same position relative to
the upstream regulatory sequences (Figure 1). This simultaneously
provides both a promoter and an insertion site for the transgene.
Early transcription occurs within the virion core shortly after entry
and cannot meaningfully be studied by transient co-transfection of
reporter plasmids [22], so previous investigations of early pro-
moter activity at the protein level used insertion of the promoter of
interest at an unnatural locus, since there is no evidence that
genomic context affects poxviral early transcription [23]. Here, we
show that four early or ‘‘immediate-early’’ [20] (also referred to as
E1.1 [19]) promoters, used at their authentic genomic loci in
MVA, are able to drive early expression of a reporter gene equal
to or exceeding the levels obtained using conventional recombi-
nants with either the p7.5 or SSP promoters. By virtue of this
approach, the insertion site is already provided with a promoter,
and the promoter has its own insertion site, thus overcoming the
need to find a suitable heterologous locus, and expanding the
options available for transgene insertion, potentially of multiple
recombinant antigens.
The protective efficacy of the first recombinant vaccinia virus
vaccines was mediated by antibody responses (e.g. against hepatitis
B and influenza [3,24]) yet their ability to induce cytotoxic T
lymphocyte responses was also recognized at the time [25].
Heterologous prime-boost vaccination regimens [26] improved
CD8
+ T cell induction and provided one of the most promising
routes to development of desperately needed new vaccines against
diseases that have resisted traditional vaccinological approaches,
such as the major global killers HIV/AIDS, tuberculosis and
malaria [27]. Recently, the combination of a recombinant
chimpanzee adenovirus boosted by MVA expressing the same
transgenic antigen has achieved unprecedented frequencies of
vaccine-induced antigen-specific CD8
+ T cells in humans [28].
Here, we show that expression of recombinant antigen from four
endogenous early or ‘‘immediate-early’’ promoters in MVA elicits
equal or slightly superior frequencies of specific CD8
+ T cells
compared to p7.5 or SSP in either single-shot or adenovirus-
prime, MVA-boost vaccination regimens in mice. We also present
an indirect comparison with mH5. Furthermore, insertion into
these loci did not adversely affect viral growth and the
recombinant viruses were genetically stable, indicating the
applicability of the resurrected and improved endogenous-pro-
moter method to vaccine design.
Materials and Methods
Model Antigen based on Renilla Luciferase
A cDNA encoding a variant of Renilla reniformis (sea pansy)
luciferase, rLuc8, which exhibits improved stability and light
output [29], was obtained from Dr Sanjiv Gambhir, Stanford
University, USA. A poxviral early transcription termination motif
(T5NT) was removed by PCR mutagenesis, such that the
isoleucine at position 48 is encoded by ATC instead of ATT.
We further modified the encoded protein by fusing two sequences
to the N-terminus: the H2-K
d restricted murine CD8
+ T cell
epitope SYIPSAEKI (Pb9) from the Plasmodium berghei circumspor-
ozoite protein [30] and the signal peptide comprising amino acids
1–28 of human tissue plasminogen activator (tPA). The sequence
MDD linked tPA and Pb9 and the sequence GS linked Pb9 and
rLuc8. A T5NT early termination sequence was placed immedi-
ately downstream of the tPA-Pb9-rLuc8PV open reading frame.
The resulting construct, tPA-Pb9-rLuc8PV, encodes a secretable,
Pb9-tagged version of rLuc, with enhanced extracellular stability
[29], and suitable for poxviral early expression.
Insertion into Endogenous Promoter Driven Loci of MVA-
BAC
Construction and generation of MVA-BAC and generation of
MVA deletion mutants using GalK recombineering [31] has been
described previously [16]. To generate recombinant MVA
(rMVA) viruses expressing tPA-Pb9-rLuc8PV under the control
of viral promoters at their natural loci (Tables 1 and 2), we
employed a modification of the GalK deletion method (Figure 1). A
cassette was constructed using conventional PCR and restriction
enzyme based cloning, comprising the tPA-Pb9-rLuc8PV open
reading frame and the bacterial GalK resistance gene. This was
amplified with Phusion (Finnzymes) as a targeting DNA for
recombineering by using long oligonucleotide primers (Eurofins
MWG Operon) to add 50 bp homology arms to the 59 and 39
ends. The primers were designed to delete the viral ORF wholly or
partially (depending on the predicted effects of deletions on
downstream genes) and to replace it with tPA-Pb9-rLuc8PV and
the bacterial selectable marker. The homology arm immediately 59
to the tPA-Pb9-rLuc8PV ORF was designed to place the initiator
codon (ATG) of the inserted ORF at the same position as that of
the deleted viral gene (Table 2). These targeting constructs were
used for MVA-BAC recombineering as previously described [16].
GalK selection was used to facilitate removal of the marker and
‘recycling’ for insertion at a second locus, though we did not take
advantage of this in the present paper.
Insertion into TK Locus for Control Constructs using
MVA-BAC
An rMVA expressing tPA-Pb9-rLuc8PV from the traditional
promoter, p7.5, inserted at the thymidine kinase (TK) locus was
Figure 1. Schematic of transgene insertion at endogenous
promoter driven locus of MVA, using B8R as an example. (A)
Surrounding open reading frames (ORFs) in the MVA genome are
indicated by white arrows, with B8R highlighted in grey. Black ‘‘p’’
above black bar indicates predicted B8R early promoter core region (see
Table 2), overlapping with the B7R ORF. The left homology arm (LHA)
and right homology arm (RHA) sequences (white boxes), each 50 bp in
length, were added by PCR to the ends of a cassette comprising a model
antigen, tPA-Pb9-rLuc8PV (narrow grey arrow) and the bacterial
selectable marker GalK (black arrow), with its bacterial promoter (small
black triangle). The LHA was designed to place the initiation codon of
tPA-Pb9-rLuc8PV in the same position as that of the B8R ORF. Crossed
lines indicate homology arm recombination events between targeting
amplicon and MVA-BAC. (B) After recombineering of this 2.4 kb
targeting amplicon into MVA-BAC to replace B8R, tPA-Pb9-rLuc8PV
was placed under control of the B8R promoter.
doi:10.1371/journal.pone.0040167.g001
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previously described [32]. We did not take advantage of this
system’s en passant capability for AphAI removal in the present
paper. The p7.5 promoter of pEP75TK was replaced with the
short synthetic promoter, SSP [12], or the mH5 promoter [11] by
standard PCR and restriction enzyme techniques. This construct
was used in parallel to generate rMVA expressing tPA-Pb9-
rLuc8PV under control of SSP.
MVA-BAC Rescue and Propagation of rMVA
The recombineered MVA-BACs were rescued to recombinant
MVA in BHK cells (obtained from ATCC via LGC Standards)
using a fowlpox virus helper as previously described [16]. To
avoid a second round of recombineering, and to establish viral
viability at an early stage, the GalK or AphAI bacterial marker
genes were not removed prior to rescue. BACs and derived
viruses were checked for identity and purity by PCR and the
sequences of the homology arms and transgenes were confirmed
at both stages. BAC-derived rMVAs were plaque-picked three
times to ensure purity, as a precautionary measure: carry-over
of GalK-negative ‘‘hitch-hikers’’ is sometimes problematic in this
positive metabolic selection system (this can alternatively, or
additionally be addressed by repeated bacterial re-streaking on
MacConkey indicator plates [33]). The viruses were amplified in
1500 cm
2 of BHK cell monolayers, partially purified over
sucrose cushions and titred in primary chicken embryo
fibroblast (CEF) cells (obtained from the Institute for Animal
Health, Compton Laboratory, UK) according to standard
practice, and purity and identity were again verified by PCR.
Since MVA-BAC has a GFP marker gene under control of the
Fowlpox virus p4B promoter [16], all the rMVAs expressed
GFP in addition to tPA-Pb9-rLuc8PV.
Adenovirus Vectored Vaccine
An E1/E3-deleted chimpanzee adenovirus, ChAd63 [34],
expressing TIP, a model epitope string antigen which also contains
the Pb9 epitope [35], was constructed as previously described [36].
ChAd63-TIP was purified by CsCl gradient ultracentrifugation
and titred by immunolabelling (ifu) using Cell Biolabs’ QuickTiter
kit modified for 96-well plates.
Luciferase Assays
For luciferase assays, a ‘‘spinoculation’’ protocol was used [37]
in order to synchronize the infection and enable prior washing of
the cells to remove rLuc activity in the inoculum (see Results).
BHK cells (5610
4 cells/well) in flat-bottom 96-well microtitre
plates were inoculated in duplicate with rMVAs at 1 pfu/cell. The
plates were centrifuged at 650G for 1h at 0uC then washed three
times with ice-cold DMEM containing 2% FCS, before being
placed at 37uC in 150 mL per well of medium which optionally
contained 40 mM cytosine arabinoside (AraC). A 20 ml aliquot of
supernatant was taken immediately after washing, then at 1 h, 2 h,
Table 1. Loci selected for insertion of endogenous promoter driven transgene by replacement of MVA open reading frame (ORF).
MVA ORF
Vaccinia
ortholog Function in vaccinia virus MVA-specific mutations Promoter activity*
Position of ATG in GenBank
U94848.1 [43]
176R B8R IFN-c soluble receptor [63] 39 inactivating truncation Early (IE | E1.1) 157621 (top strand)
041L F11L Cell motility (RhoA inhibitor) [64] Fragmented (040L+041L) Early ( E | E1.1) 33771 (bottom strand)
027L K6L Unknown; fragmented putative
monoglyceride lipase (K6L+K5L)
Fragmented; see Results Early (IE | E1.1) 24694 (bottom strand)
157L A44L 3b hydroxysteroid dehydrogenase [46] 1 amino acid substitution Early (IE | E1.2) 15377 (bottom strand)
005R C11R Vaccinia viral growth factor (VGF) [65] None Early (IE | E1.1) 10203 (top strand)
168R B2R Unknown; fragmented (B2R+B3R) Fragmented (168R+169R) Early (IE | E1.2) 152144 (top strand)
*Designations in brackets refer to categorisation into immediate early (IE) or early (E) clusters by microarray analysis [20], and into the corresponding E1.1 and E1.2
clusters by deep sequencing [19], of vaccinia virus mRNA.
doi:10.1371/journal.pone.0040167.t001
Table 2. Sequences of promoters, with transcriptional and translational (ATG) start sites shown capitalised, and the predicted early
promoter core sequences underlined [19].
B8R atattattcaaaatatgatttttaaaAatttaaaatatattatcacttcagtgacagtagtcaaataacaaacaacaccATG
F11L
a aaaaaagtgaaaaacaatattattttTatcgttggttgtttcactATG
A44L gtaaaatagaataagtagtctgatattaTgagtggcagcaATG
K6L
b ataaaacataaaaataatatgatcatcaAacgaactgttaatattgatagttatataacgtgaatcATGagtgcaaactgtatgttcaatctggacaATG
C11R atattactgaattaataatAtaaaattcccaatcttgtcataaacacacactgagaaacagcataaacacaaaatccatcaaaaATG
B2R
b cgataaaaattaaaaaaTaacttaatttattattgatctcgtgtgtacaaccgaaatcATGgcgatgttttacgcacacgctctcggtgggtacgacgagaatcttcATG
p7.5
c taaaagtagaaaatatattctaatttatTgcacggtaaggaagtagaatcataaagaacagt–MCS
SSP
c taaaaattgaaattttattttttttttttTgaatataaataa–MCS
aThe italicised ‘t’ in F11L was mutated during recombineering to identity with vaccinia virus Western Reserve strain (VACV-WR).
bThe second (downstream) ATG was used in the recombinant viruses described in the text. This is the ATG of the ORF as originally annotated in MVA [43]. The upstream
ATG, however, likely represents the authentic translational start site in vaccinia virus, encoding a protein that is severely truncated in MVA by a small deletion (see text).
cConventional insertion of promoter linked to ORF at the TK locus of MVA. Dashes indicate appendage of multiple cloning site (MCS).
doi:10.1371/journal.pone.0040167.t002
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washed in PBS and lysed in a volume of 150 mL. The rLuc activity
in 10 mL aliquots of these samples was quantified using the Renilla
Luciferase Assay System (Promega) and a Varioskan Flash
luminometer (Thermo).
Mouse Immunogenicity
Female BALB/C mice aged 6 to 8 weeks were immunized
intramuscularly (i.m.) in the tibialis muscles (total volume 50 mL)
with a total of 10
6 pfu of rMVA, or with 10
8 ifu of ChAd63
followed eight weeks later with 10
6 pfu of rMVA for the
heterologous prime boost regimen. Mice were used in accor-
dance with the UK Animals (Scientific Procedures) Act 1986
under project license number 30/2414 granted by the UK Home
Office. For induction of short-term anaesthesia, animals were
anaesthetised using vaporised IsoFlo
H. Splenocytes were har-
vested seven (single-shot) or fourteen (prime-boost) days post-
immunization for analysis by IFN-c ELIspot or flow cytometry
with intracellular cytokine staining (ICS), both as previously
described [16,36], using re-stimulation with 1 mg/mL Pb9
peptide [30]. In the absence of peptide restimulation, the
frequency of IFN-c
+ CD8
+ cells was ,0.1% by flow cytometry
or ,50 sfc/10
6 splenocytes by ELIspot.
Viral Genetic Stability Assay
For serial passage, CEF cells in 25 cm
2 flasks were inoculated
with 100 ml of crude lysate (or initially with 1 pfu/cell) incubated
until all cells were infected as determined by epifluorescence
microscopy for GFP (2–3 days), and subjected to triple freeze
thaw. The process was repeated 10 times, after which the viruses
were titred on CEF cells. Note that all the BAC-derived rMVAs
expressed GFP in addition to tPA-Pb9-rLuc8PV (see above).
Titres fell within the range of 2.4 to 3.8 6 10
5 pfu/mL. To
determine what proportion of viruses retained expression of the
model antigen tPA-Pb9-rLuc8PV, CEF cells in 150 cm
2 flasks
were infected at 0.001 pfu/cell and 2 days later, single GFP
+
trypsinized cells were sorted into individual wells of 96-well plates
using the CyCLONE robotic module of a MoFlo (Dako
Cytomation) flow cytometer. These plates were seeded with 5
610
4 BHK cells per well and 3 days later the wells were scored
positive or negative for GFP by epifluorescence microscopy
before quantification of rLuc activity in the cell lysates as above.
Not all BHK wells were GFP
+, owing to unavoidable errors in
the MoFlo droplet identification combined with the imperfect
correlation between presence of infectious virions and GFP
positivity in the sorted CEF cells. Wells were scored positive or
negative for rLuc based on a cut-off of three standard deviations
above the geometric mean of the light units detected in GFP
–
(i.e., uninfected) wells. Any genetic instability at the tPA-Pb9-
rLuc8PV insertion locus would result in absence of luciferase
activity in a GFP
+ well.
Viral Growth Rate Assay
The growth rates of rMVAs were determined by GFP
fluorescence as previously described [32]. Briefly, BHK cells
(seeded at 5610
4 cells/well) in a black-walled, clear-bottom 96-
well plate were infected in duplicate with rMVAs at various
multiplicities of infection and GFP fluorescence was quantified
every 6 min for 36 h using a BMG FluoSTAR fluorimeter
equipped with 37uC+5% CO2 incubation.
Results
Selection of Non-essential, Highly Expressed Genes for
Replacement with a Transgenic ORF
To investigate promoter activity at the natural locus by deleting
a non-essential MVA gene and replacing it with the ORF of
interest, leaving the latter under control of the deleted gene’s
natural promoter (Figure 1), we selected, amongst many possibil-
ities, six non-essential loci in MVA (Table 1), on the basis of the
following criteria.
First, we identified highly expressed early or ‘‘immediate-early’’
(IE)genesfromthevacciniavirusmicroarraydata ofAssarsson et al.
[20]. (At the time, the more recent deep RNA sequencing paper, in
whichIEgenesweredesignated E1.1[19],hadnotbeenpublished).
RecombinantMVAandotherpoxvirusesareattractingattentionas
vaccinevectorsowingtotheirabilitytoinduceantigen-specificCD8
+
T cells [38]. Such responses to vaccinia virus infection are directed
almost exclusively against early viral antigens [39–42]. We hypoth-
esized that the early or IE promoters driving expression of these
antigens would therefore be capable of eliciting high frequencies of
CD8
+T cells against arecombinant antigen inMVA.
Second, since the viral ORF is deleted concomitant with
insertion, it is important that the targeted gene is non-essential.
From this point of view, MVA has the advantage that many of its
genes were inactivated during attenuation by serial passage
[43,44]. Of the six selected genes (Table 1), three are fragmented,
and B8R has a truncation that is known to inactivate the encoded
IFN-c binding protein [45]. The immunodominant CD8
+ T cell
epitope in C57BL/6 mice is encoded by B8R [40], making this
gene a very strong candidate. Both A44L [46,47] and C11R
[48,49] are virulence factors that do not affect vaccinia virus
replication in vitro; and we have shown that deletion of A44L [16]
or C11R (Cottingham et al., unpublished data) does not affect
MVA immunogenicity.
Third, we avoided ORFs with upstream regions carrying MVA-
specific mutations, since these might affect promoter function
compared to vaccinia virus (e.g. F7L, K1L). We did not exclude
F11L on this basis, but instead reverted an MVA-specific
substitution just upstream of the initiation codon back to identity
with vaccinia virus (Table 2).
Generation of Recombinant Viruses by MVA-BAC
Recombineering
Recombineering primers were designed to insert a model
reporter transgene, tPA-Pb9-rLuc8PV, into the selected loci
(Table 1), replacing the viral ORF (Figure 1). This was done such
that the ATG of the deleted MVA ORF was replaced with that of
the transgene (Table 2), followed by the bacterial selectable marker
GalK. Recombineering reactions were efficient in all cases, as was
found previously [16]. As controls, we constructed traditional-style
recombinants employing the p7.5 and SSP promoters to drive the
same transgene at the TK locus, also using BAC recombineering
[32]. These promoters were linked to the ORF by conventional
ligation, so contained an intervening sequence containing part of
the multiple cloning site. The BACs were rescued, amplified, and
semi-purified, and the eight resulting viral preparations (Table 1)
had yields ranging from 1.8 6 10
9 to 5.4 6 10
9 pfu/mL (final
volume ,0.5 mL from 1500 cm
2 flask area), which lies in the
expected range for conventional and BAC-derived MVA [32].
The purity and identity of the recombinant viruses were verified
by PCR analysis (not shown). Insertion into each of the six
candidate loci did not therefore affect the efficiency of BAC rescue
or the viral productivity.
Using Endogenous Promoters in MVA
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e40167MVA Transgene Expression in vitro Driven by
Endogenous Promoters at Their Natural Loci
The tPA-Pb9-rLuc8PV transgene allows facile detection of
renilla luciferase in the culture supernatant by virtue of the N-
terminal tPA signal peptide and eight stability-enhancing point
mutations [29]. All six of the selected promoters (Table 2) were
able to drive expression of rLuc (Figure 2), which was measured
8 h after infection of BHK cells in the absence or presence of
AraC to inhibit post-replicative gene expression. In the presence
of AraC, the B8R, F11L, A44L and C11R promoters at their
authentic loci (pB8R, pF11L, pA44L and pC11R) produced
rLuc levels similar to that produced by p7.5 or SSP; however,
in the absence of the inhibitor, the late promoter activity of
p7.5 and SSP allowed higher protein expression. This was
expected because p7.5 and SSP have combined early and late
promoter activity, unlike the other promoters tested. In the case
of pK6L and pB2R, the expression of rLuc was unexpectedly
poor in both conditions: indeed, for pB2R, no luciferase was
detected in the absence of AraC (the signal seen in the presence
of the inhibitor at 8 hours post-infection in Figure 2 is likely
due to prolonged, and therefore detectable, early gene
expression in this condition).
MVA Orthologs of K6L and B2R are Truncated and
Fragmented Pseudogenes
Closer inspection of the sequences upstream of the MVA
orthologs of K6L (MVA026L) and B2R (MVA168R) revealed
fragmentation due to small deletions at the 59 ends which we had
overlooked during design of the constructs (Table 2). These
mutations are found in addition to more obvious fragmentation in
MVA, and the situation is complex because these genes are
themselves fragmented in vaccinia virus compared to ancestral
poxviruses such as cowpox virus (CPXV; NCBI RefSeq
NC_003663.2). Vaccinia virus K5L/K6L (and WR036) are
fragments of CPXV045; and vaccinia virus B2R/B3R are fragments
of CPXV197. In MVA (GenBank U94848.1), these are annotated
as the multi-ORF pseudogenes MVA026L and MVA168R and the
smaller ORF remnants (MVA027L and MVA169R) do not feature
in the current annotation at all, but are described only in the
original paper [43]. We mistakenly targeted the initiation codons
of MVA027L and MVA168R without realising until later that these
do not contain the authentic K6L and B2R initiation codons, which
are found further upstream (see Table 2). These ATGs lie much
closer to the mean 40 bp distance from the early transcriptional
start sites [19] and initiate severely truncated ORFs comprising the
authentic N-terminal 14 plus 1 nonsense amino acids (K6L)o r3 0
plus 2 nonsense amino acids (B2R), as the result, in both cases, of
a 20 bp deletion in MVA relative to vaccinia virus (positions
24691..24692 and 152186..152187 in U94848). Thus, it appears
that these two genes, themselves fragments of larger cowpoxviral
ORFs, are further inactivated in MVA by small frame-shifting
deletions near their 59 ends (and in the case of the B2R ortholog,
even more fragmented into MVA168/MVA169 by yet another
deletion, of 14 bp). The use of the non-authentic ATG for
insertion of tPA-Pb9-rLuc8PV (Table 2) presumably led to
inefficient translation initiation and poor expression, suggesting
that it is the upstream, non-annotated and severely truncated small
ORFs containing the vaccinia virus start codons that are efficiently
translated in MVA. The recombinant viruses employing the non-
authentic initiation codons of K6L and B2R were not investigated
further in this study.
Kinetic Analysis of Transgene Expression in vitro
In measuring recombinant protein production by tPA-Pb9-
rLuc8PV expressing viruses, we found that rLuc was readily
detectable in the sucrose-concentrated viral preparations, espe-
cially in the case of SSP, the strongest late promoter. (The data in
Figure 2 show the difference in rLuc levels from 1 h to 8 h post-
infection; see legend). Although certain recombinant proteins [50]
(and cellular proteins [51]) have been reported to be incorporated
into various compartments of the vaccinia virion, we considered
this was unlikely in the case of tPA-Pb9-rLuc8PV, since it is
predicted to be a secreted, soluble protein. We therefore utilized
a ‘‘spinoculation’’ [37] and washing protocol at 0uC before return
to 37uC to allow viral entry. This effectively removed rLuc from
the inoculum, confirming that its presence was indeed simply due
to carry-over of soluble protein into the sucrose preparation, and
allowing serial analysis of rLuc in the culture supernatant at
various time points post-infection (Figure 3; compare ‘‘inoculum’’
to ‘‘0 h’’).
Three of the four remaining endogenous promoters were
remarkably similar to SSP in their ability to direct rLuc expression
in the presence of AraC (Figure 3B), with p7.5 and pA44L
exhibiting slightly weaker expression. When post-replicative
expression was allowed, in the absence of the inhibitor, SSP
drove very high levels of rLuc and the late promoter activity of
p7.5 was also apparent (Figure 3A). Since pF11L, pA44R, pC11R
and pB8R lack predicted late activity, the continued increase in
rLuc levels at 8 – 12 h post-infection in the absence compared to
the presence of AraC is likely the result of a second round of viral
replication by progeny virus.
Figure 2. Activity of endogenous promoters compared to p7.5
and SSP in vitro. BHK cells were infected with 1 pfu/cell of
recombinant MVA carrying tPA-Pb9-rLuc8PV under the control of the
indicated promoters. Renilla luciferase activity in the culture superna-
tant was quantified at 8 h post-infection. Cells were either untreated
(grey bars) or exposed to 40 mM AraC during and after infection (open
bars), to inhibit post-replicative gene expression. Data shown are the
mean and standard deviation of duplicates after subtraction of signal at
1 h post-infection and are representative of two independent experi-
ments.
doi:10.1371/journal.pone.0040167.g002
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We used the Pb9 epitope fused to the N-terminus of our
reporter construct tPA-Pb9-rLuc8PV to determine the ability of
expression by pF11L, pA44R, pC11R and pB8R to elicit CD8
+ T
cells against the recombinant protein in vivo, in comparison to the
traditional-style p7.5 and SSP promoter driven recombinants. One
week after vaccination of mice with 10
6 pfu rMVA, the
frequencies of Pb9-specific CD8
+ T cells were determined by
intracellular cytokine staining (ICS) (Figure 4A) and IFN-c
ELIspot (Figure 4B). All the viruses elicited potent responses;
and while by ELIspot there was no significant difference between
the groups (p=0.08 by one way ANoVA), pF11L and pC11R
drove significantly higher CD8
+ T cell frequencies than pA44L
when the responses were measured by ICS (p,0.05 by Newman-
Keuls post-test following one-way ANoVA; overall p=0.005). In
both readouts, and in other independent experiments (data not
shown), the trend was the same, in that pF11L and pC11L elicited
the highest CD8
+ T cell frequencies, similar to SSP, with p7.5 and
pB8R and A44L exhibiting slightly lower immunogenicity.
A heterologous prime-boost vaccination regimen employing
a recombinant adenoviral vector followed 8 weeks later by rMVA
expressing the same antigen is capable of eliciting extremely high
frequencies of CD8
+ T cells in mice [52], monkeys [34,53] and
humans [28]. We therefore performed a comparison of the
endogenous promoters to p7.5 and SSP using this regimen, by
priming with a chimpanzee adenovirus vector, ChAd63 [34],
expressing the Pb9 epitope fused to GFP [35], and boosting at day
56 with rMVA. The frequencies of Pb9-specific CD8
+ T cells were
determined by IFN-c ELIspot two weeks post-boost (Figure 4C).
Surprisingly, SSP elicited the lowest frequency, and was statisti-
cally significantly worse than pC11R (p,0.05 by Newman-Keuls
post-test following one-way ANoVA; overall p=0.04), but the
immune responses were not otherwise distinguishable. This may
indicate that very abundant late gene expression may not be
optimal for CD8
+ T cell induction in an adenovirus-MVA prime-
boost regimen; however, the data clearly show that all of the
endogenous promoter driven insertion loci perform as well as the
traditional p7.5 promoter in this context.
Comparison of mH5 and p7.5 Promoters using tPA-Pb9-
rLuc8PV Antigen
The mH5 promoter has enhanced early gene expression and
cellular immunogenicity compared to p7.5 [11]. Although we did
not perform a direct head-to-head comparison of the endogenous
promoter driven insertion loci with a recombinant employing the
mH5 promoter, we did evaluate the expression and immunoge-
nicity of tPA-Pb9-rLuc8PV driven by mH5 compared with p7.5
when inserted as a traditional-style cassette at the TK locus by
BAC recombineering. In agreement with what is to our knowledge
the only other direct head-to-head comparison of murine CD8
+ T
cell induction by vaccination with recombinant MVAs employing
the p7.5 and mH5 promoters [54], we observed a statistically
significant increase in the frequency of Pb9-specific IFN-c
+ CD8
+
T cells determined by ICS in the splenocytes of mice vaccinated
with the mH5 construct (p=0.03 by t-test) versus p7.5 (Figure 5B).
Using our tPA-Pb9-rLuc8PV reporter system, we did not observe
dramatic differences in levels of rLuc in vitro at early time-points
post-infection, unlike the original finding with a b-galactosidase
reporter [11] and another study using cytomegalovirus pp65 [55],
though the augmented late promoter activity of mH5 was
apparent (Figure 5A).
The frequencies of antigen-specific IFN-c
+ CD8
+ T cells elicited
by mH5-driven antigen were 1.56-fold higher than those elicited by
p7.5-drivenantigen(95%confidenceinterval[CI]from1.06-foldto
2.07-fold) (Figure 5B). For the purposes of comparison with the flow
cytometry data shown in Figure 4A, the ICS responses to pC11R-
driven antigen were 1.90-fold higher (95% CI from 1.50- to 2.30-
fold), and to pF11L-driven antigen 2.02-fold higher (95% CI from
1.43- to 2.61-fold), than those raised against p7.5-driven antigen.
Figure 3. Timecourse of endogenous promoter activities
compared to p7.5 and SSP in vitro. BHK cells were ‘‘spinoculated’’
(see Materials and Methods) with 1 pfu/cell of recombinant MVA
carrying tPA-Pb9-rLuc8PV under the control of the indicated promoters.
Renilla luciferase activity was quantified in the inoculum, the culture
supernatant at various time points post-infection, and in the cell lysate
at 24 h post-infection. Cells were either untreated (A) or exposed to
40 mM AraC during and after infection (B), to inhibit post-replicative
gene expression. Data shown are the mean and standard deviation of
duplicates and are representative of two independent experiments.
doi:10.1371/journal.pone.0040167.g003
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does not Adversely Affect Viral Growth
Although all the BAC-derived rMVAs expressing tPA-Pb9-
rLuc8PV inserted to replace viral ORFs produced the expected
viral yields during production (.10
9 pfu/mL, see above), we
nevertheless wished to measure the growth rate, since increasing
inoculum or delaying harvest during propagation can compensate
for reduced growth. All the BAC-derived rMVAs carried
a separate GFP marker gene driven by the p4B late promoter of
fowlpox virus [16], so we were able to use real-time fluorimetry as
a proxy for viral growth rate. We have previously used this assay to
show that derivation of MVA by the BAC method does not affect
viral growth [32]. The growth curves of MVA lacking tPA-Pb9-
rLuc8PV (but containing the GFP marker) and of the rMVAs
employing pB8R, pF11L and pA44R to drive tPA-Pb9-rLuc8PV
overlaid almost exactly (Figure 6), but rMVA using pC11R (i.e.
lacking C11R, encoding the vaccinia growth factor) surprisingly
exhibited a more rapid increase in GFP fluorescence and reached
a slightly higher plateau. The viral yield after sucrose concentra-
tion did not differ significantly from that of other rMVA (3.7 6
10
9 pfu/mL; see above). Nevertheless, we therefore conclude that
insertion of the transgene at any of these four loci, concomitant
with deletion of the targeted viral ORF, did not impair growth.
Genetic Stability of rMVA with Transgenes Inserted at
Novel Loci
EachofthefourrMVAsemployingthepB8R,pF11L,pA44Land
pC11Rpromoterswaspassaged10timesinCEFsatlowmultiplicity
Figure 4. Cellular immunogenicity of recombinant MVA antigen (tPA-Pb9-rLuc8PV) driven by endogenous promoters compared to
p7.5 and SSP in single-shot (A, B) or heterologous prime-boost (C) vaccination regimens. For single-shot (A, B), BALB/c mice were
immunized i.m. with 10
6 pfu rMVA) and splenic CD8
+ T cell responses to Pb9 peptide were determined 7 days later by intracellular cytokine staining
and flow cytometry (A) or IFN-c ELIspot (B). For prime-boost (C), BALB/c mice were immunized i.m. with 10
8 infectious units of AdCh63-tPA-Pb9-
rLuc8PV and 56 days later received 10
6 pfu rMVA. At day 70 (14 days post-boost), splenic CD8
+ T cell responses to Pb9 peptide were determined by
IFN-c ELIspot. Circles represent the responses of individual mice, with lines indicating the mean and the error bars showing SEM. See text for
statistical analysis. The data shown are representative of two independent experiments.
doi:10.1371/journal.pone.0040167.g004
Figure 5. (A) Timecourse of activity of mH5 promoter compared to p7.5 in vitro. BHK cells were ‘‘spinoculated’’ (see Materials and Methods) with
1 pfu/cell of recombinant MVA carrying tPA-Pb9-rLuc8PV under the control of the indicated promoters. Renilla luciferase activity was quantified in
the inoculum and then in the culture supernatant at various time points post-infection. Cells were either untreated or exposed to 40 mM AraC during
and after infection as indicated, to inhibit post-replicative gene expression. Data shown are the mean and standard deviation of duplicates. The data
shown are representative of two independent experiments. (B) Cellular immunogenicity of recombinant MVA antigen (tPA-Pb9-rLuc8PV) driven by
mH5 compared to p7.5 in a single-shot vaccination regimens. BALB/c mice were immunized i.m. with 10
6 pfu rMVA and splenic CD8
+ T cell responses
to Pb9 peptide were determined 7 days later by intracellular cytokine staining and flow cytometry. Circles represent the responses of individual mice,
with lines indicating the mean and the error bars showing SEM. See text for statistical analysis. The data shown are representative of two independent
experiments.
doi:10.1371/journal.pone.0040167.g005
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Pb9-rLuc8PV, we flow sorted individual infected cells into
microtitre plate wells, amplified the viruses by addition of BHK
cells, and quantified rLuc expression in infected versus uninfected
wells, which were differentiated via the viral GFP marker gene.
Uninfected cells were the result of droplet loss during sorting or to
lack of infectious progeny from GFP
+ cells (the cells were lysed
immediatelyaftersorting).AllGFP
+wellscontaineddetectablerLuc
(Figure7),indicatingthattransgeneinsertionatthesenovelinsertion
loci does not in itself lead to genetic instability.
Discussion
Here we show that using BAC recombineering it is straightfor-
ward to replace a non-essential poxviral ORF with a transgenic
ORF and precisely retain the position of the initiation codon. This
allows expression of the foreign protein by the promoter of the
targeted gene, enabling assessment of the activity of the promoter
at its natural locus, in terms of protein expression and
immunogenicity. We demonstrate this in MVA using the orthologs
of C11R, F11L, B8R and A44L, and compared early protein
expression and immunogenicity with that achievable using the
traditional p7.5 or SSP promoters coupled to the transgenic ORF
and inserted at the thymidine kinase locus. Two promoters,
pC11R and pF11L, enabled augmented CD8
+ T cell responses
compared to p7.5, and the magnitude of this difference was similar
to the increment observed with mH5 compared to p7.5 in separate
experiments. Furthermore, we demonstrate that insertion at all
four of these sites does not result in genetic instability or impair
viral growth or achievable titre.
Unexpectedly, the rMVA with the rLuc reporter gene inserted
undercontrolofpC11R,andthereforelackingtheC11vacciniavirus
growthfactor,exhibitedaslightlyfasterincreaseinGFPfluorescence
(expressed from a separate, late promoter driven transgene) during
viralreplication,despitehavingaverysimilartitreafteramplification
andsucroseconcentration.C11hasbeenreportedtoactivateNF-kB
(S.MartinandJ.Shisler,personalcommunication),soanabsenceof
induction of cellular transcriptional programmes via this pathway
might perhaps underlie this phenomenon. Since we have not
performed traditional growth curves, we cannot conclude that this
difference in GFP kinetics necessarily represents enhanced growth,
but this does not affect the conclusion, reached in combination with
the yield data, that the growth of MVA expressing a pC11L-driven
transgene inplace ofC11Ris unimpaired.
In two other cases K6L and B2R, we mis-positioned the insertion,
andselectedadownstreamATG(Table2).Theannotatedinitiation
codons of MVA026L and MVA168R in the MVA genomic sequence
(GenBank U94848.1) do not correspond to the authentic ATGs
utilized in vaccinia virus K6L and B2R. Small MVA-specific
deletions near the 59 ends of these ORFs result in frame shifts, such
that each authentic vaccinia virus ATG initiates a very severely
truncated ORF of only 14 or 30 amino acids. Reporter gene
expression using the 39 (non-authentic) ATG was poor, indicating
thattheseN-terminalpolypeptidefragmentsaretheonlypartsofthe
putative vaccinia virus B2 and K6 proteins that are efficiently
expressed in MVA, presumably because translation initiation from
the 59 ATG is favoured, as previously reported [56]. These findings
highlighttheimportanceofpositioningtheORFcorrectlyrelativeto
the promoter – one of the factors that likely impeded the uptake of
endogenous promoter usage as a method for construction of
recombinantpoxvirusesinthe1980s[1,5].Investigationsofwhether
Figure 6. Growth rates of rMVA expressing tPA-Pb9-rLuc8PV under the control of endogenous MVA promoters in comparison to
MVA lacking tPA-Pb9-rLuc8PV but containing the same GFP marker gene (nrMVA). BHK cells were infected with viruses at 1 pfu/cell (A),
0.5 pfu/cell (B) or 0.25 pfu/cell (C) and fluorescence of the viral GFP marker gene was quantified every 6 minutes for 36 h using a BMG FluoSTAR
equipped with 37uC and 5% CO2 incubation. Thick lines show the mean of two replicates and adjacent thin lines of the same colour represent the
standard deviation. The data shown are representative of two independent experiments. Fluorescence intensity is expressed in arbitrary units.
doi:10.1371/journal.pone.0040167.g006
Figure 7. Genetic stability of rMVA expressing tPA-Pb9-
rLuc8PV under control of endogenous promoters. Viruses were
subjected to ten serial passages in CEFs, titred, and inoculated onto BHK
cells at 0.001 pfu/cell. After 2 days, the cells were harvested and
individually sorted into the wells of a 96-well plate using the CyCLONE
attachment of a MoFlo flow cytometer. Two days later, renilla luciferase
activity in the cell lysates was determined after scoring of wells as
positive (+) or negative (2) for the viral GFP marker gene, indicating
infection in the well. A cut-off of three standard deviations above the
geometric mean of the GFP (dashed line labelled 3s) was used to score
GFP
+ and GFP
2 wells luciferase positive (Luc
+) or negative (Luc
2). Wells
in which cell monolayers were lost during processing were excluded.
Raw data for the pB8R recombinant (A) and well scores for all viruses (B)
are shown.
doi:10.1371/journal.pone.0040167.g007
Using Endogenous Promoters in MVA
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e40167insertion at the authentic vaccinia virus ATG improves transgene
expression atthe K6Land B2Rloci arecurrently on-going. Wehave
not investigated whether intervening exogenous sequences lacking
initiation codons, such as those derived from a multiple cloning site
(as in our control p7.5 and SSP rMVAs and other traditionally-
derived recombinants) affect transcription: this would not be
expected based on current understanding of poxviral transcription
[22].Itisintriguingtospeculateonthemechanismofdeletionatthe
K6LandB2RlociinMVA(thereisarepeated9 bpor5 bpsequence
separated by 20 bp at these loci in vaccinia virus, which may be
relevant) and on the potential selective advantage of the severe
truncationofK6andB2duringderivationofMVAbyserialpassage
– especially given that there is an additional fragmenting deletion in
the B2R region of MVA, and that these vaccinia virus genes are
themselves fragments of larger ancestral ORFs found (for example)
in cowpox virus.
How well does the protein expression level we observed in MVA
correlate with recent vaccinia virus transcriptomic data? We
selected the promoters based on strong early mRNA expression in
vaccinia virus microarray data [20], which has subsequently been
complemented by a deep RNA sequencing study [19]. With
regard to the four promoters investigated here, there is some
disagreement both between and within these two studies, and with
our protein-level data. The two methods were not unanimous in
the clustering of C11R, F11L, B8R and A44L into the IE (E1.1) or
E (E1.2) classes (Table 1), and we could not detect any meaningful
difference in protein expression at the earliest time point (Figure 3).
The rank order of mRNA abundance differed between early time
points and an AraC treated group in the microarray, and within
replicates in the deep sequencing study. Nevertheless, either C11R
or F11L transcripts are the most abundant by both methods; and
A44L transcripts consistently the least abundant, with those of
other ORFs targeted here generally occupying an intermediate
position – including p7.5, which was analysed at its natural locus
(WR001/C29L/B29R). Thus, there is generally good agreement in
the rank order of the promoter activities, as determined here by
protein expression and immunogenicity (Figures 2, 3, and 4), and
the abundance of mRNA from the driven vaccinia virus genes.
However, there is some discrepancy in the magnitude of the
difference. For example, there was an approximately 20-fold
difference in mRNA copy number between the highest and lowest
values for these five promoters; yet at the protein level (Figures 2
and 3) the range is much lower – threefold at most. This suggests
that the promoter may not be the only factor affecting mRNA
abundance in poxviruses: polyadenlyation or degradation rates
could, for example, also play a role in a manner that is not
apparent when an identical reporter gene is utilized.
CD8
+ T cell responses to vaccinia virus are directed almost
exclusively against early viral genes [39–42]. In agreement with
this, we found that the cellular immunogenicity of rMVA
employing early promoters was similar to those using early/late
promoters (p7.5 and SSP), either as the sole immunogen or as
a boost after priming with an adenoviral vector. The strongest
promoters, pF11L and pC11R, elicited the highest frequencies of
CD8
+ T cell responses in the single-shot regimen. Two published
approaches have enhanced the activity of early poxviral
promoters: mutation of individual unfavourable nucleotides [23]
of the core region of the H5R promoter, known as mH5 [11], and
tandem insertion of multiple synthetic early promoter core regions,
known as pHyb [57]. Consistent with our observations using wild-
type pC11R and pF11L, both these interventions improve CD8
+
T cell induction by a modest factor after a single rMVA
vaccination compared to use of p7.5 [54,57].
We did not perform a direct head-to-head comparison of mH5
with pC11R or pF11L, but we present our own comparison of p7.5
andmH5inFigure5.UseofmH5todriveexpressionofrecombinant
antigen enabled about 1.5-fold higher CD8
+ T cell responses
compared with p7.5, versus about 2-fold using pC11R or pF11L
compared with p7.5 in a separate experiment. Thus, it seems likely
from this indirect comparison that pC11R or pF11L are at least as
potent as mH5. Since the 95% confidence intervals of the
improvements relative to p7.5 overlap (see Results), we conclude
that further studies are required to establish the hierarchy more
precisely.
We have also not yet investigated whether expression of
a transgenic antigen from pC11R or pF11L modifies the pattern
of immunodominance compared to viral antigens observed upon
repeated immunization with rMVA, as reported for pHyb [57], nor
whether the activities of these or similar endogenous promoters
could be enhanced by rational modification, similar to mH5
[11,23].An updated endogenous promoter driven transgenic
strategy as described here has a number of potential advantages
for generation of an rMVA-based vaccine product. If CD8
+ T cells
are the desired immune response, then late antigen expression is
unnecessary, so promoters like those identified here, or variants
thereof, would be ideal for maximal cellular immunogenicity but
with minimal selective pressure resulting from excessive transgene
expression due to strong late promoter activity in vitro, which can
cause genetic instability [55,58]. Alternatively, there are suitable
early/late promoters in MVA that could be harnessed in the same
manner,iflatepromoteractivityweredesirable,e.g.forinductionof
humoral responses against transgenic antigen. The use of endoge-
nous promoters (with possible modifications) at their authentic loci
may also offer an improved strategy for multivalent rMVA
expressing multiple antigens from the same or different pathogens
– another idea first demonstrated using vaccinia virus in the early
1980s [59]. Since homologous recombination is a major mutagenic
mechanism in rMVA [14], introduction of the best conventional
promoter, mH5, at multiple loci may inevitably carry an increased
risk of instability, although such designs have been reported to be
genetically stable [55].
To illustrate speculatively the potential applicability of the
findings described here, two recent papers describing candidate
‘flu vaccines based on rMVA may be considered: one using
haemagglutinin (HA) to induce protective antibodies in ferrets [60]
and one using a nucleoprotein–matrix protein 1 (NP+M1) fusion
protein to elicit T cell responses against these more conserved
internal antigens in humans, potentially providing heterosubtypic
immunity [61]. These studies used either the mH5 or p7.5
promoter inserted at the TK locus – the tried and tested,
conventional approach. What would be the best design of an
rMVA expressing two or more flu antigens, to combine these
approaches? As an example, one could express HA traditionally,
for example using mH5 at the TK locus, for antibody induction;
and NP and M1 under control of pF11L and pC11L at their own
loci, for CD8
+ T cell induction. The identification of additional
endogenous promoter driven insertion loci in combination with
conventional approaches would allow expression of even more
transgenic antigens. This could be valuable for development of
new vaccines against more complex pathogens, for example,
malaria parasites, where a multi-component vaccine targeting
more than one stage of the life cycle is likely to be required to
attain useful protective efficacy [62]. Even taking only the liver
stage, it is already clear that vaccines that induce antibodies
against the circumsporozoite protein or T cells against TRAP can
each provide partial protection in humans, making them strong
candidates for inclusion in a future combination vaccine [62].
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e40167Although viral vectored vaccines are showing promise in human
clinical trials, it is also important that products have optimal
immunogenicity and manufacturability. The application of BAC
recombineering technology to poxviruses allows a precision of
genetic manipulation that has the potential to allow realisation of
ideas first conceived nearly 30 years ago.
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